Cargando…
Exploiting signaling rewiring in cancer cells with co‐existing oncogenic drivers
The development of tailored therapies designed to specifically target driver oncogenes has initiated a revolutionary era in cancer biology. The availability of a growing number of selective inhibitors has generated novel experimental and clinical paradigms. These represent an opportunity and a chall...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620112/ https://www.ncbi.nlm.nih.gov/pubmed/37872865 http://dx.doi.org/10.1002/1878-0261.13547 |